Henry Schein shares surge 10.16% intraday after reporting record Q3 results and raising full-year guidance.

Henry Schein surged 10.16% intraday after reporting record Q3 2025 results, raising full-year non-GAAP EPS guidance to $4.88–$4.96 and sales growth to 3–4%. The company highlighted $3.3 billion in revenue (up 5.2% YoY), strong operating income improvement, and $200 million in value creation initiatives over the next few years. Management emphasized accelerated sales growth across all segments, including dental and medical distribution, and a strategic partnership amendment allowing KKR to increase ownership to 19.9%. Analysts noted the results exceeded estimates for both revenue and adjusted EBITDA, reinforcing confidence in operational recovery post-cyber incident and long-term growth. The stock’s sharp intraday rally aligned with the upbeat guidance and execution progress on margin-enhancing initiatives.